皮肤鳞状细胞癌（cSCC）是由表皮鳞状细胞引起的第二常见的皮肤癌。如果及早发现和治疗，大多数 cSCC 病例的预后良好；然而，某些情况可能具有攻击性。 cSCC 的主要危险因素是长时间暴露在阳光下的紫外线辐射，导致 DNA 突变。还观察到其他危险因素，包括药物不良反应，特别是免疫抑制剂。对美国食品和药物管理局不良事件报告系统 (FAERS) 进行了查询，所有报告的 cSCC 事件作为药物不良事件均与受影响患者的人口统计数据一起记录。 1997年至2023年间，总共报告了4,792例cSCC作为药物不良事件的病例。化疗药物来那度胺的cSCC不良事件病例最多。与 cSCC 相关的前 10 种药物中有 9 种具有免疫抑制特性。虽然男性患与皮质类固醇和钙调神经磷酸酶抑制剂相关的 cSCC 的几率较高，但女性患与单克隆抗体相关的 cSCC 的几率较高。老年患者占 cSCC 病例的大多数，占 59.7%。根据 FAERS 数据库的数据，由于某些药物的副作用，cSCC 病例持续增加，其中大多数具有免疫抑制特征。由于缺乏概述与 cSCC 最相关的药物的最新文献，我们旨在更好地说明这一点以及患者人口统计数据，以便更好地指导临床医生开具这些药物。© 2024。作者。

Cutaneous squamous cell carcinoma (cSCC) is the second most common type of skin cancer arising from squamous cells of the epidermis. Most cases of cSCC have a good prognosis if detected and treated early; however, certain cases can be aggressive. The primary risk factor for cSCC is prolonged ultraviolet radiation from sun exposure, leading to DNA mutations. Other risk factors have also been observed, including adverse reactions to medications, particularly immunosuppressants. A query of the Food and Drug Administration Adverse Events Reporting System (FAERS) was done, and all reported events of cSCC as adverse events to medication were recorded along with demographic data of patients affected. A total of 4,792 cases of cSCC as an adverse event to medication were reported between 1997 and 2023. Lenalidomide, a chemotherapeutic drug, had the most cases of cSCC as an adverse event. Nine of the top 10 drugs associated with cSCC had immunosuppressive characteristics. While males had higher odds of cSCC associated with corticosteroids and calcineurin inhibitors, females had higher odds of cSCC related to monoclonal antibodies. Geriatric patients accounted for the majority of cSCC cases at 59.7%. Drawing on data from the FAERS database, there's been a consistent increase in cSCC cases as a side-effect to certain medications, with most having immunosuppressive characteristics. Since there is a lack of up-to-date literature overviewing the most implicated medications for cSCC, we aimed to illustrate this better, as well as patient demographics, to better guide clinicians when prescribing these medications.© 2024. The Author(s).